4 / 31
•
Not all mCRC patients receive treatment beyond 1
st
line
1
•
1
st
-line agents may have potential to modify tumour biology and/or
sensitise/desensitise the tumour to later treatment lines
2,3
100
53
28
13
0
10
20
30
40
50
60
70
80
90
100
1st line
2nd line
3rd line
4th line
Proportion of patients (%)
The importance of 1
st
-line treatment choice in mCRC
1. Abrams TA, et al. J Natl Cancer Inst 2014. 2. Modest DP, et al. J Clin Oncol 2015. 3. Wainberg ZA, Drakaki A. Expert Opin Biol Ther 2015..
N = 4877
†
1
st
line
2
n
line
3
r
line
4
th
line